GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (FRA:IQI) » Definitions » Debt-to-EBITDA

Incannex Healthcare (FRA:IQI) Debt-to-EBITDA : -0.02 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Incannex Healthcare Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Incannex Healthcare's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.15 Mil. Incannex Healthcare's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.23 Mil. Incannex Healthcare's annualized EBITDA for the quarter that ended in Mar. 2024 was €-22.37 Mil. Incannex Healthcare's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Incannex Healthcare's Debt-to-EBITDA or its related term are showing as below:

FRA:IQI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.46   Med: -0.06   Max: -0.02
Current: -0.03

During the past 13 years, the highest Debt-to-EBITDA Ratio of Incannex Healthcare was -0.02. The lowest was -0.46. And the median was -0.06.

FRA:IQI's Debt-to-EBITDA is ranked worse than
100% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.71 vs FRA:IQI: -0.03

Incannex Healthcare Debt-to-EBITDA Historical Data

The historical data trend for Incannex Healthcare's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare Debt-to-EBITDA Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.02 - - -

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.03 N/A -0.02 -0.02

Competitive Comparison of Incannex Healthcare's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incannex Healthcare's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's Debt-to-EBITDA falls into.



Incannex Healthcare Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Incannex Healthcare's Debt-to-EBITDA for the fiscal year that ended in Jun. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -9.615
=0.00

Incannex Healthcare's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.148 + 0.228) / -22.368
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Incannex Healthcare  (FRA:IQI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Incannex Healthcare Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (FRA:IQI) Business Description

Traded in Other Exchanges
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.